US SB3271 | 2019-2020 | 116th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 2-1)
Status: Introduced on February 11 2020 - 25% progression, died in committee
Action: 2020-02-11 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 11 2020 - 25% progression, died in committee
Action: 2020-02-11 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs, and for other purposes.
Title
Fairness in Orphan Drug Exclusivity Act
Sponsors
Sen. Bill Cassidy [R-LA] | Sen. Tammy Baldwin [D-WI] | Sen. Jeanne Shaheen [D-NH] |
History
Date | Chamber | Action |
---|---|---|
2020-02-11 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB4712 (Related) 2020-11-18 - Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Health
Licensing and registrations
Marketing and advertising
Prescription drugs
Drug safety, medical device, and laboratory regulation
Health
Licensing and registrations
Marketing and advertising
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/senate-bill/3271/all-info |
Text | https://www.congress.gov/116/bills/s3271/BILLS-116s3271is.pdf |